Tumor antigens and antigen-presenting capacity in breast cancer

Pathobiology

Volumn 70, Issue 6, 2002, Pages 324-332

  McDermott, Raymond S ^a,e   Beuvon, Frédéric ^b   Pauly, Marc ^c   Pallud, Claude ^d   Vincent Salomon, Anne ^a   Mosseri, Veronique ^a   Pouillart, Pierre ^a   Scholl, Susy M ^a  

^a INSTITUT CURIE   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c Rech le Can/les Maladies du Sang ^*  (France)

^d CENTRE RENÉ HUGUENIN   (France)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

Breast cancer; CD1a; MHC II; p53; Tumor immune response

Indexed keywords

ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD45RO ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 1; PROTEIN P53; T6 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CELL ACTIVITY; CELL INFILTRATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DENDRITIC CELL; DNA SEQUENCE; EVALUATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LYMPHOCYTE; ONCOGENE NEU; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SAMPLE; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR CELL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGEN PRESENTATION; ANTIGENS, CD1; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CA-15-3 ANTIGEN; DNA MUTATIONAL ANALYSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038649315     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071272     Document Type: Article

References (51)

1. Gilboa E: The makings of a tumor rejection antigen. Immunity 1999;11:263-270.
2. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-365.
3. Marincola F: Mechanisms of immune escape and immune tolerance; in: Biologic Therapy of Cancer, ed 3. Philadelphia, LWW, 1998.
4. Bevan MJ: Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976;143:1283-1288.
5. Hohn H, Pilch H, Gunzel S, Neukirch C, Hilmes C, Kaufmann A, Seliger B, Maeurer MJ: CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol 1999;163:5715-5722.
6. Chen PW, Ullrich SE, Ananthaswamy HN: Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes. J Leukoc Biol 1994;56:469-474.
7. Armstrong TD, Clements VK, Ostrand-Rosenberg S: MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol 1998;160:661-666.
8. Ostrand-Rosenberg S: Tumor immunotherapy: The tumor cells as an antigen-presenting cell. Curr Opin Immunol 1994;6:722-727.
9. Hillenbrand EE, Neville AM, Coventry BJ: Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours. Br J Cancer 1999;79:940-944.
10. Lespagnard L, Gancberg D, Rouas G, Leclercq G, de Saint-Aubain Somerhausen N, Di Leo A, Piccart M, Verhest A, Larsimont D: Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: A study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer 1999;84:309-314.
11. Bartek J, Petrek M, Vojtesek B, Bartkova J, Kovarik J, Rejthar A: HLA-DR antigens on differentiating human mammary gland epithelium and breast tumours. Br J Cancer 1987;56:727-733.
12. Moller P, Mattfeldt T, Gross C, Schlosshauer P, Koch A, Koretz K, Moldenhauer G, Kaufmann M, Otto HF: Expression of HLA-A, -B, -C, -DR, -DP, -DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplastic mammary epithelium, fibroadenoma, adenoma, and carcinoma of the breast. Am J Pathol 1989;135:73-83.
13. Lutzker SG, Lattime EC: Use of dendritic cells to immunize against cancers overexpressing p53. Clin Cancer Res 2001;7:2-4.
14. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
15. Graham RA, Burchell JM, Taylor-Papadimitriou J: The polymorphic epithelial mucin: Potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 1996;42:71-80.
16. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillart P, Lidereau R: Anti-colony-stimulating factor-1 antibody staining in primary breast adencarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994;86:120-126.
17. Pauly M, Schmitz M, Kayser I, Tureci O, Lagoda P, Seitz G, Dicato M: Ki-ras oncogene and p53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma-carcinoma sequence model. Eur J Cancer 1997;33:2265-2272.
18. Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, Salvadori B, Veronesi U: Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1,400 node-negative breast cancers. Clin Cancer Res 1996;2:2007-2013.
19. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18:574-583.
20. Blumberg RS, Gerdes D, Chott A, Porcelli SA, Balk SP: Structure and function of the CD1 family of MHC-like cell surfacec proteins. Immunol Rev 1995;147:5-29.
21. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190:1417-1426.
22. Tsuge T, Yamakawa M, Tsukamoto M: Infiltrating dendritic/Langerhans cells in primary breast cancer. Breast Cancer Res Treat 2000;59:141-152.
23. Lucin K, Iternicka Z, Jonjic N: Prognostic significance of T-cell infiltrates, expression of beta 2-microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 1994;190:1134-1140.
24. Koretz K, Moldenhauer G, Majdic O, Moller P: Correlation of HLA-D/Ii antigen expression in breast carcinoma with local lymphohistiocytic infiltration reveals considerable dysregulation in a subset of tumors. Int J Cancer 1989;44:816-822.
25. Qi L, Rojas JM, Ostrand-Rosenberg S: Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol 2000;165:5451-5461.
26. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
27. Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E: TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 1998;4:203-210.
28. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartmann S, et al: TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14:71-75.
29. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M, et al: Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 1995;25:1765-1769.
30. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA: Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995;92:11993-11997.
31. Lewko B, Zoltowska A, Stepinski J, Roszkiewicz A, Moszkowska G: Dendritic and cancer cells in the breast tumors: An immunohistochemical study: Short communication. Med Sci Monit 2000;6:892-895.
32. Hilders CG, Houbiers JG, van Ravenswaay Claasen HH, Veldhuizen RW, Fleuren GJ: Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest 1993;69:651-659.
33. Lee AH, Happerfield LC, Millis RR, Bobrow LG: Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast. Br J Cancer 1996;74:796-801.
34. Zuk JA, Walker RA: Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J Pathol 1987;152:275-285.
35. Zeid NA, Muller HK: S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993;25:338-343.
36. Ioachim-Velogianni E, Stavropoulos NE, Kitsiou E, Stefanaki S, Agnantis NJ: Distribution of CD1a-positive Langerhans cells and lymphocyte subsets in transitional cell carcinoma of the urinary bladder: An immunohistological study on frozen sections. J Pathol 1995;177:401-406.
37. Hachisuga T, Fukuda K, Uchiyama M, Matsuo N, Iwasaka T, Sugimori H: Immunohistochemical study of p53 expression in endometrial carcinomas: Correlation with markers of proliferating cells and clinicopathologic features. Int J Gynecol Cancer 1993;3:363-368.
38. Valcuende-Cavero F, Febrer-Bosch MI, Castells-Rodellas A: Langerhans' cells and lymphocytic infiltrate in AIDS-associated Kaposi's sarcoma: An immunohistochemical study. Acta Derm Venereol 1994;74:183-187.
39. Wright-Browne V, McClain KL, Talpaz M, Ordonez N, Estrov Z: Physiology and pathophysiology of dendritic cells. Hum Pathol 1997;28:563-579.
40. Sheen-Chen SM, Chou FF, Eng HL, Chen WJ: An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. Surgery 1994;116:510-515.
41. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F: Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991;2:47-54.
42. Lazzaro B, Anderson AE, Kajdacsy-Balla A, Hessner MJ: Antigenic characterization of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases. Appl Immunohistochem Mol Morphol 2001;9:234-241.
43. Feinmesser M, Sulkes A, Morgenstern S, Sulkes J, Stern S, Okon E: HLA-DR and beta-2-microglobulin expression in medullary and atypical medullary carcinoma of the breast: Histopathologically similar but biologically distinct entities. J Clin Pathol 2000;53:286-291.
44. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF: Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992;147:1636-1642.
45. Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, Fujimoto M, Yokojama K, Ogata T: Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 1999;187:191-199.
46. Melief CJ, Offringa R, Toes RE, Kast WM: Peptide-based cancer vaccines. Curr Opin Immunol 1996;8:651-657.
47. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL: Natural history of HLA expression during tumour development. Immunol Today 1993;14:491-499.
48. Tartour E, Gey A, Sastre-Garau X, Lombard Surin I, Mosseri V, Fridman WH: Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst 1998;90:287-294.
49. Nakagomi H, Pisa P, Pisa EK, Yamamoto Y, Halapi E, Backlin K, Juhlin C, Kiessling R: Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 1995;63:366-371.
50. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K, Modlin R, Wollman J, Dubinett SM: Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995;55:3847-3853.
51. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC: Gradual loss of T-helper 1 population in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995;87:1478-1483.